RJA
ANIK icon

Raymond James & Associates’s Anika Therapeutics ANIK Stock Holding History

Raymond James & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,154
Closed -$279K – 3996
2020
Q4 		$279K Buy
6,154
+492
+9% +$18.7K ﹤0.01% 3160
2020
Q3 		$200K Sell
5,662
-65
-1% -$2.35K ﹤0.01% 3212
2020
Q2 		$216K Buy
+5,727
New +$189K ﹤0.01% 3079
2020
Q1 		– Sell
-5,905
Closed -$306K – 3501
2019
Q4 		$306K Sell
5,905
-58
-1% -$3.37K ﹤0.01% 3072
2019
Q3 		$327K Sell
5,963
-1,380
-19% -$70.9K ﹤0.01% 2956
2019
Q2 		$298K Sell
7,343
-378
-5% -$13.8K ﹤0.01% 3017
2019
Q1 		$233K Buy
7,721
+1,600
+26% +$54.8K ﹤0.01% 3134
2018
Q4 		$206K Sell
6,121
-1,259
-17% -$45.4K ﹤0.01% 3108
2018
Q3 		$311K Sell
7,380
-278
-4% -$11K ﹤0.01% 3003
2018
Q2 		$245K Buy
7,658
+3,498
+84% +$144K ﹤0.01% 3138
2018
Q1 		$207K Buy
+4,160
New +$235K ﹤0.01% 3116
2013
Q4 		– Sell
-13,787
Closed -$329K – 1962
2013
Q3 		$329K Buy
13,787
+601
+5% +$13.5K ﹤0.01% 1750
2013
Q2 		$224K Buy
+13,186
New +$190K ﹤0.01% 1813

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Raymond James & Associates's ANIK Position: Q1 2021 in Review

Raymond James & Associates sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 6,154 shares — an estimated $279K sold.

Raymond James & Associates first reported a position in ANIK in Q2 2013 and held it in 13 quarters. The position peaked at $329K in Q3 2013. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Raymond James & Associates reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Raymond James & Associates sold 6,154 Anika Therapeutics shares in Q1 2021, an estimated $279K.
  • Raymond James & Associates first reported a position in Anika Therapeutics in Q2 2013 and held it in 13 quarters.
  • Raymond James & Associates's Anika Therapeutics position peaked at $329K in Q3 2013.
  • 145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.